Processa Pharmaceuticals
PCSA
18 hedge funds and large institutions have $376K invested in Processa Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.04% less ownership
Funds ownership: 5.63% → 4.59% (-1%)
12% less capital inflows, than outflows
Capital inflows: $169K | Capital outflows: $192K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$66.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$35.5K |
| 3 |
Spinnaker Trust
Portland,
Maine
|
+$34.4K |
| 4 |
Two Sigma Investments
New York
|
+$8.26K |
| 5 |
Coastal Bridge Advisors
Westport,
Connecticut
|
+$5.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$107K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$49.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.6K |
| 4 |
Millennium Management
New York
|
-$6.61K |
| 5 |
Mirador Capital Partners
Pleasanton,
California
|
-$4.88K |
PCSA Hedge Fund Activity: Q4 2023 in Review
18 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2023, worth a combined $376K — up 7.6% from $350K a quarter earlier.
Fund positioning in PCSA was balanced in Q4 2023: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $66.7K. The largest seller was Walleye Capital, exiting entirely with an estimated $107K sold.
- 18 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $376K of Processa Pharmaceuticals stock for Q4 2023, up 7.6% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q4 2023 and 4 closed out, a net change of 0 holders.
- The largest Processa Pharmaceuticals buyer in Q4 2023 was Citadel Advisors, an estimated $66.7K added.
- The largest Processa Pharmaceuticals seller in Q4 2023 was Walleye Capital, an estimated $107K sold.
Based on aggregated 13F filings for Q4 2023.